Patent · US Active

CpG-adjuvanted SARS-CoV-2 virus vaccine

US11684669B2 · kind B2 · utility

1Cited by

4References

30Claims

0Family size

Assignees

Valneva Austria GmbH · AT
DYNAVAX TECHNOLOGIES CORPORATION · US

Inventors

Andreas Meinke · Pressbaum, AT
Michael Möhlen · Marburg, DE
Christoph Reinisch · Siegenfeld, AT
Robert Schlegl · Siegenfeld, AT
Christian Taucher · Wien, AT
John D. CAMPBELL · Emeryville, US
David Novack · Emeryville, US
Robert Janssen · Palm Springs, US
Jürgen Heindl-Wruss · Wien, AT

Key dates

Filing date	Sep 10, 2021
Grant date	Jun 27, 2023
Priority date	—
Expiry date	Sep 10, 2041

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.